scholarly article | Q13442814 |
P2093 | author name string | Yutaka Kimura | |
Yasuto Naoi | |||
Takeshi Kato | |||
Takahiko Tanigawa | |||
Taro Hayashi | |||
Eiji Kurokawa | |||
Hitoshi Yamamoto | |||
Nobuteru Kikkawa | |||
Shohei Iijima | |||
P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
Clinical implications of dihydropyrimidine dehydrogenase inhibition. | Q33708379 | ||
Report on nationwide pooled data and cohort investigation in UFT phase II study. | Q36433925 | ||
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats | Q41196248 | ||
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study | Q44583571 | ||
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas | Q67274828 | ||
Continuous 5-Fluorouracil Infusion in Advanced Gastric Carcinoma | Q68480479 | ||
Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil | Q69975754 | ||
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study] | Q69976405 | ||
Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts | Q70355508 | ||
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators | Q71665880 | ||
Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats | Q72092575 | ||
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group | Q73143101 | ||
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients | Q77809280 | ||
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug | Q78206833 | ||
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 34-39 | |
P577 | publication date | 2003-01-01 | |
P1433 | published in | Gastric Cancer | Q15724608 |
P1476 | title | A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice | |
P478 | volume | 6 Suppl 1 |